One thing both the Trump and Biden administrations have agreed on is that the U.S. needs to expand domestic manufacturing, and soon.
The pharmaceutical industry in particular has outsourced much of its manufacturing to take advantage of lower costs and more lax environmental laws in other countries. This has left Americans reliant on overseas drugmakers, largely in India and China, and vulnerable to gaps in the supply chain when quality issues or a pandemic halts production.
Image: Ronald T. Piervincenzi – Source: United States Pharmacopeia